These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
5. Long-term efficacy and safety of adalimumab on a severe case of hidradenitis suppurativa. Caposiena Caro RD; Cannizzaro MV; DI Raimondo C; DI Matteo E; Botti E; Rossi P; Bianchi L Ital J Dermatol Venerol; 2021 Feb; 156(1):101-102. PubMed ID: 30350561 [No Abstract] [Full Text] [Related]
6. Tildrakizumab for the treatment of hidradenitis suppurativa in patients previously treated with adalimumab: a 30-month experience. Koszegi B; Wilson A; Stone C; Satgé F; Cowan TL; Murrell DF Clin Exp Dermatol; 2023 Oct; 48(11):1266-1269. PubMed ID: 37434310 [No Abstract] [Full Text] [Related]
7. Adalimumab medium-term dosing strategy in moderate-to-severe hidradenitis suppurativa: integrated results from the phase III randomized placebo-controlled PIONEER trials. Jemec GBE; Okun MM; Forman SB; Gulliver WPF; Prens EP; Mrowietz U; Armstrong AW; Geng Z; Gu Y; Williams DA; Teixeira HD; Kimball AB Br J Dermatol; 2019 Nov; 181(5):967-975. PubMed ID: 30916379 [TBL] [Abstract][Full Text] [Related]
8. Two Cases of Hidradenitis Suppurativa Treated with Adalimumab at the Department of Dermatology and Venereology, Clinical Hospital Mostar. Lovrić I; Brkić J; Ćorluka M; Čović M; Pejić J; Zeljko Penavić J Acta Dermatovenerol Croat; 2021 Jul; 29(2):108-110. PubMed ID: 34477078 [TBL] [Abstract][Full Text] [Related]
9. Real-world safety and effectiveness of adalimumab in patients with hidradenitis suppurativa: 12-week interim analysis of post-marketing surveillance in Japan. Hayashi N; Hayama K; Takahashi K; Kurokawa I; Okazaki M; Kashiwagi T; Iwashita E; Terui T J Dermatol; 2022 Apr; 49(4):411-421. PubMed ID: 35040156 [TBL] [Abstract][Full Text] [Related]
10. Improvement in Hidradenitis Suppurativa and quality of life in patients treated with adalimumab: Real-world results from the HARMONY Study. Hafner A; Ghislain PD; Kovács R; Batchelor R; Katoulis AC; Kirby B; Banayan H; Schonbrun M J Eur Acad Dermatol Venereol; 2021 Nov; 35(11):2277-2284. PubMed ID: 34320249 [TBL] [Abstract][Full Text] [Related]
11. Certolizumab pegol in the treatment of severe hidradenitis suppurativa after adalimumab failure: A real-life experience. Esme P; Akoglu G; Dalkıran CD; Caliskan E Dermatol Ther; 2022 Nov; 35(11):e15782. PubMed ID: 35996992 [TBL] [Abstract][Full Text] [Related]
12. Clinical and Ultrasonographic Profile of Adalimumab-treated Hidradenitis Suppurativa Patients: A Real-life Monocentric Experience. Chiricozzi A; Giovanardi G; Garcovich S; Malvaso D; Caldarola G; Fossati B; Guerriero C; De Simone C; Peris K Acta Derm Venereol; 2020 Jun; 100(13):adv00172. PubMed ID: 32421198 [TBL] [Abstract][Full Text] [Related]
13. Long-term safety of adalimumab for patients with moderate-to-severe hidradenitis suppurativa. Tzanetakou V; Stergianou D; Giamarellos-Bourboulis EJ Expert Opin Drug Saf; 2020 Apr; 19(4):381-393. PubMed ID: 32098513 [No Abstract] [Full Text] [Related]
14. Switching from adalimumab originator to biosimilars in hidradenitis suppurativa: What's beyond cost-effectiveness? Roccuzzo G; Rozzo G; Burzi L; Repetto F; Dapavo P; Ribero S; Quaglino P Dermatol Ther; 2022 Nov; 35(11):e15803. PubMed ID: 36062429 [TBL] [Abstract][Full Text] [Related]
15. Pharmaceutical Benefits Scheme listing of adalimumab for hidradenitis suppurativa: Is hidradenitis suppurativa a life-changing drug or does lifestyle change the drug? Vekic DA; Frew JW Australas J Dermatol; 2018 Aug; 59(3):e243-e244. PubMed ID: 29285755 [No Abstract] [Full Text] [Related]
16. Adalimumab Treatment in Women With Moderate-to-Severe Hidradenitis Suppurativa from the Placebo-Controlled Portion of a Phase 2, Randomized, Double-Blind Study. Gottlieb A; Menter A; Armstrong A; Ocampo C; Gu Y; Teixeira HD J Drugs Dermatol; 2016 Oct; 15(10):1192-1196. PubMed ID: 27741335 [TBL] [Abstract][Full Text] [Related]
17. Efficacy and Safety of Bimekizumab in Moderate to Severe Hidradenitis Suppurativa: A Phase 2, Double-blind, Placebo-Controlled Randomized Clinical Trial. Glatt S; Jemec GBE; Forman S; Sayed C; Schmieder G; Weisman J; Rolleri R; Seegobin S; Baeten D; Ionescu L; Zouboulis CC; Shaw S JAMA Dermatol; 2021 Nov; 157(11):1279-1288. PubMed ID: 34406364 [TBL] [Abstract][Full Text] [Related]
18. Clinical experience of the use of adalimumab in the management of hidradenitis suppurativa. Comparison of response rates with Crohn disease. Moyano B; Clemente A; Marín-Jiménez I; Martorell A Actas Dermosifiliogr; 2016 Sep; 107 Suppl 2():43-50. PubMed ID: 28081769 [TBL] [Abstract][Full Text] [Related]
19. Concomitant psoriasis and hidradenitis suppurativa responsive to adalimumab therapy: A case series. Yen CF; Huang YH; Chi CC Indian J Dermatol Venereol Leprol; 2021; 87(2):223-226. PubMed ID: 31389375 [TBL] [Abstract][Full Text] [Related]
20. Clinical response rates, placebo response rates, and significantly associated covariates are dependent on choice of outcome measure in hidradenitis suppurativa: A post hoc analysis of PIONEER 1 and 2 individual patient data. Frew JW; Jiang CS; Singh N; Grand D; Navrazhina K; Vaughan R; Krueger JG J Am Acad Dermatol; 2020 May; 82(5):1150-1157. PubMed ID: 31881294 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]